---
title: "Promising Medical Stocks To Follow Now - March 23rd"
description: "MarketBeat's stock screener highlights five medical stocks to watch: Pfizer, Merck & Co., UnitedHealth Group, Eli Lilly, and AbbVie. These companies are notable for their high trading volumes and sign"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232868101.md"
published_at: "2025-03-23T18:02:20.000Z"
---

# Promising Medical Stocks To Follow Now - March 23rd

> MarketBeat's stock screener highlights five medical stocks to watch: Pfizer, Merck & Co., UnitedHealth Group, Eli Lilly, and AbbVie. These companies are notable for their high trading volumes and significant market presence in pharmaceuticals and healthcare. Pfizer's stock is currently at $26.20, Merck at $93.44, and UnitedHealth at $517.72, with each company showing varying market caps and financial ratios. The healthcare sector remains dynamic, influenced by regulatory changes and market trends.

-   Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

Pfizer, Merck & Co., Inc., UnitedHealth Group, Eli Lilly and Company, and AbbVie are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares in companies that operate within the healthcare industry, including those involved in pharmaceuticals, biotechnology, medical devices, and healthcare services. These investments can offer exposure to innovations in medical treatments and technologies, though their performance is often subject to regulatory changes and market dynamics specific to the healthcare sector. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

## Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

-   These Stocks Missed on Earnings, But Will Rebound Next Quarter

Shares of NYSE:PFE traded up $0.01 on Friday, reaching $26.20. The company's stock had a trading volume of 349,778,786 shares, compared to its average volume of 36,645,908. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a market cap of $148.61 billion, a P/E ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The company has a 50-day simple moving average of $26.17 and a 200 day simple moving average of $27.04. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Read Our Latest Research Report on PFE

## Merck & Co., Inc. (MRK)

-   After a Reset Year, Is Moderna Stock Poised for a Comeback?

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of NYSE:MRK traded down $1.29 on Friday, reaching $93.44. The company's stock had a trading volume of 68,284,470 shares, compared to its average volume of 10,227,995. Merck & Co., Inc. has a 52-week low of $81.04 and a 52-week high of $134.63. The company has a market cap of $236.03 billion, a P/E ratio of 13.88, a PEG ratio of 0.77 and a beta of 0.35. The company has a 50-day simple moving average of $93.00 and a 200 day simple moving average of $101.07. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.

Read Our Latest Research Report on MRK

## UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Shares of UNH stock traded up $6.42 during trading hours on Friday, reaching $517.72. 10,192,902 shares of the stock were exchanged, compared to its average volume of 4,088,232. UnitedHealth Group has a 12-month low of $436.38 and a 12-month high of $630.73. The company has a current ratio of 0.83, a quick ratio of 0.91 and a debt-to-equity ratio of 0.74. The company's 50-day moving average price is $510.19 and its 200-day moving average price is $547.11. The firm has a market capitalization of $473.57 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 1.37 and a beta of 0.62.

Read Our Latest Research Report on UNH

## Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY stock traded down $3.13 during trading hours on Friday, reaching $839.44. 5,957,460 shares of the stock were exchanged, compared to its average volume of 3,151,645. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company's 50-day moving average price is $835.99 and its 200-day moving average price is $839.05. The firm has a market capitalization of $795.93 billion, a price-to-earnings ratio of 71.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Read Our Latest Research Report on LLY

## AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded down $1.98 during trading hours on Friday, reaching $209.98. 16,647,005 shares of the stock were exchanged, compared to its average volume of 5,243,989. AbbVie has a 12-month low of $153.58 and a 12-month high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The company's 50-day moving average price is $194.49 and its 200-day moving average price is $188.67. The firm has a market capitalization of $370.68 billion, a price-to-earnings ratio of 87.49, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61.

Read Our Latest Research Report on ABBV

## See Also

-   MarketBeat's Top Five Stocks to Own in March 2025
-   AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
-   3 ETFs to Ride the VIX Surge During Market Volatility
-   Why Williams-Sonoma Will Hit Fresh Highs in 2025
-   Alphabet Stock Becomes a Low-Risk, High-Reward Play
-   Affirm Stock: Should You Buy the Dip After Walmart Setback?

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)
- [UNH.US - Unitedhealth](https://longbridge.com/en/quote/UNH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| DELL, SPOT, UNH: The World's Biggest Hedge Fund Is Bottom Fishing the Market | Bridgewater Associates, the largest hedge fund with $136 billion in assets, made significant investments in underperform | [Link](https://longbridge.com/en/news/276384705.md) |
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/en/news/276252273.md) |
| Medical Properties Hike on Q4 Results | Medical Properties Trust, Inc. (NYSE: MPT) reported Q4 2025 results with net income of $0.03 and Normalized Funds from O | [Link](https://longbridge.com/en/news/276349240.md) |
| Novo Nordisk's Wegovy Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral Glp-1S in Obesity | Novo Nordisk's Wegovy® (semaglutide) pill, approved by the FDA in December 2025, has seen strong uptake among physicians | [Link](https://longbridge.com/en/news/276452735.md) |
| Earnings Outlook For Community Healthcare | Community Healthcare (NYSE:CHCT) is set to release its quarterly earnings report on February 17, 2026, with analysts exp | [Link](https://longbridge.com/en/news/276073723.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
